Replies to post #323780 on ORIONS Money Stocks

[onkelhubert]

i'm in NEPT (owns large part of ACST) cause i think it will profit from both the ACST catalyst and the next Q results which should be good because of the new facility that opened back in june this year.

[$oldier Hard]

ACST, I did see this when they announced there fins back in July. They always are but wth.

Top-line results for the recently completed TRIFECTA and PK trial are expected by the end of September 2014, with full data for both trials coming out in the following quarter. Top-line data for the TRIFECTA trial will include the efficacy of CaPre(R) in lowering triglycerides, along with its impact on other lipid markers, including high-density lipoprotein (HDL) and non-HDL as well as low-density lipoprotein (LDL).